Independent health-science reporting · Evidence ratedEvidence rated
Section
Genomic profiling, biomarker-guided therapy, and the infrastructure — sequencing, tumor boards, reimbursement — that determines whether precision medicine reaches ordinary clinics.
An ancillary analysis of a phase III trial evaluates the prognostic value of different PD-L1 scoring methods in patients treated with chemotherapy alone.
A retrospective study of real-world data evaluates treatment patterns and survival outcomes for advanced HER2-negative gastroesophageal adenocarcinoma.
Researchers discover that cycloechinulin targets a specific signaling pathway to suppress tumor growth in patient-derived organoids.
Post-treatment detection of circulating tumor DNA 2 years after chemotherapy is strongly associated with distant recurrence and poorer overall survival.
An analysis of molecular profiling in primary liver cancer outlines the opportunities and limitations of integrating genomic, proteomic, and metabolomic signatures.
An emerging mass spectrometry approach helps identify naturally presented peptides to guide personalized brain tumor therapies.
Researchers mapped the molecular landscape of pontine diffuse midline glioma to locate targets for next-generation immunotherapies.
A retrospective study of the PROMISE clinical genomic database associates current smoking at diagnosis with worse overall survival and specific somatic mutations.
A meta-analysis of nearly 2,000 patients suggests that measuring soluble PD-L1 in blood could help personalize immunotherapy for non-small cell lung cancer.
A systematic review highlights the diagnostic potential of nucleic acid aptamers in lung cancer while detailing the scientific and market hurdles to clinical adoption.
